ReviewTrends in biotechnology2021
Build a Sustainable Vaccines Industry with Synthetic Biology.
Review in Trends in biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cyber-biological convergence: a systematic review and future outlook.Frontiers in bioengineering and biotechnology · 2024Pooled it
- Application progress and biosafety challenges of gene editing and synthetic biotechnology in diagnosis, treatment and prevention of infectious diseases.Biosafety and health · 2025Review
- On-Chip DNA Assembly via Dielectrophoresis.Micromachines · 2025Article
- Construction ofVaccines · 2023Article
- Review
- Safety risks and ethical governance of biomedical applications of synthetic biology.Frontiers in bioengineering and biotechnology · 2023Article
- Synthetic biology in Indonesia: Potential and projection in a country with mega biodiversity.Biotechnology notes (Amsterdam, Netherlands) · 2023Review
- Pandemic preparedness: synthetic biology and publicly funded biofoundries can rapidly accelerate response time.Nature communications · 2022Article
- Synthetic biology in Europe: current community landscape and future perspectives.Biotechnology notes (Amsterdam, Netherlands) · 2022Article
- Biotechnology Applications of Cell-Free Expression Systems.Life (Basel, Switzerland) · 2021Review
- Building the UK's industrial base in engineering biology.Engineering biology · 2021Review
- Review
- Article
- Building Biofoundry India: challenges and path forward.Synthetic biology (Oxford, England) · 2021Review
- Thailand's Synthetic Biology Strategy.Engineering biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vaccines industry has not changed appreciably in decades regarding technology, and has struggled to remain viable, with large companies withdrawing from production. Meanwhile, there has been no let-up in outbreaks of viral disease, at a time when the biopharmaceuticals industry is discussing downsizing. The distributed manufacturing model aligns well with this, and the advent of synthetic biology promises much in terms of vaccine design. Biofoundries separate design from manufacturing, a hallmark of modern engineering. Once designed in a biofoundry, digital code can be transferred to a small-scale manufacturing facility close to the point of care, rather than physically transferring cold-chain-dependent vaccine. Thus, biofoundries and distributed manufacturing have the potential to open up a new era of biomanufacturing, one based on digital biology and information systems. This seems a better model for tackling future outbreaks and pandemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.